Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
46 pending office actions • 25 art units • 45 examiners • 0 of 46 (0%) have an AI response strategy ready • 45 patents granted in the last 365 days
City of Hope manages a portfolio with 45 pending office actions, primarily in the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 44 distinct examiners and 24 distinct art units. This count of 24 distinct art units suggests that the organization's innovations span many different specialized biological and pharmaceutical fields. The presence of 44 distinct examiners shows that the workload is distributed across the patent office. Such a wide distribution requires a prosecution strategy to manage the various standards of different departments.
The busiest examiner for the organization is BELYAVSKYI, MICHAIL A, who is currently handling 2 busiest examiner pending office actions. Despite the total of 45 pending office actions, the workload is decentralized, as evidenced by the 44 distinct examiners involved. This means that almost every pending case is being reviewed by a different official. Practitioners should note that the results in a specific matter are unlikely to influence the outcomes of other cases in this diverse portfolio. BELYAVSKYI, MICHAIL A is an official assigned to these matters.
Based on the USPTO statutory response window for each pending office action. 24 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 24 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (2%) |
| §103 only | 12 (26%) |
| §102 only | 3 (7%) |
| §112 only | 5 (11%) |
| Double-patenting + other | 7 (15%) |
| Multi-statute (no §101) | 18 (39%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELYAVSKYI, MICHAIL A | 2 | 64.2% | +27.6% |
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| POPA, ILEANA | 1 | 21.4% | +15.1% |
| BURKHART, MICHAEL D | 1 | 62.3% | +11.7% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.4% |
| WANG, RUIXUE | 1 | 57.4% | +17.8% |
| CHESTNUT, BARRY A | 1 | 73.5% | +6.4% |
| GIBBS, TERRA C | 1 | 63.7% | +10.3% |
| GANGLE, BRIAN J | 1 | 76.7% | +14.7% |
| LANDSMAN, ROBERT S | 1 | 81.3% | +13.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18842728 | PCNA INHIBITORS AND USES THEREOF | WARD, PAUL V | — |
| 18682713 | CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING gD AND ONCOLYTIC VIRUSES FOR CANCER THERAPY AND TREATMENT OF HSV | LANDSMAN, ROBERT S | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18255503 | PREVENTION AND TREATMENT OF GRAFT-VERSUS-HOST DISEASE (GVHD) | CESARE, JOSEPH DAVID | 8d overdue |
| 18284413 | CAR T CELL THERAPY AND IFN GAMMA | LEE, YIE CHIA | 9d |
| 18265544 | COMPOUNDS AND METHODS TO TREAT CYSTIC FIBROSIS | PRONZATI, GINA | 12d |
| 18026335 | EX VIVO EXPANSION OF REGULATORY T CELLS FOR SUPPRESSION OF GRAFT VERSUS HOST DISEASE | JUEDES, AMY E | 15d |
| 18361492 | METHODS OF TREATING A CORONAVIRUS INFECTION | KLINKEL, KORTNEY L | 28d |
| 18653869 | COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY | GIBBS, TERRA C | 29d |
| 18023536 | NOVEL CELL LINES, METHODS OF PRODUCING NATURAL KILLER CELLS AND USES THEREOF | LUNDE, GRACE HENRY | 34d |
| 18271026 | NATURAL KILLER CELLS ENGINEERED TO REDUCE OR ELIMINATE CBL-B AND USES THEREOF | SUNSHINE, HANNAH LOUISE | 48d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18277367 | TRUNCATED DOMAIN IV EGFR AND USES THEREOF | BELYAVSKYI, MICHAIL A | 28d overdue |
| 18653869 | COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY | GIBBS, TERRA C | 29d |
| 18816718 | T CELLS FOR EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS AND OTHER RECEPTORS | POPA, ILEANA | — |
| 18754973 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | BURKHART, MICHAEL D | — |
| 18711338 | METHODS OF PREVENTING, TREATING, OR REDUCING THE SEVERITY OF CORONAVIRUS DISEASE 2019 (COVID-19) | KINSEY WHITE, NICOLE ERIN | — |
| 18711088 | METHODS OF PREVENTING, TREATING, OR REDUCING THE SEVERITY OF COVID-19 IN IMMUNOCOMPROMISED BLOOD CANCER PATIENTS | WANG, RUIXUE | — |
| 18702614 | CLOSTRIDIUM BUTYRICUM COMPOSITIONS AND METHODS OF USING THE SAME | GANGLE, BRIAN J | — |
| 18682713 | CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING gD AND ONCOLYTIC VIRUSES FOR CANCER THERAPY AND TREATMENT OF HSV | LANDSMAN, ROBERT S | — |
| Art Unit | Apps |
|---|---|
| 1675 | 4 |
| 1644 | 3 |
| 1635 | 2 |
| 1645 | 2 |
| 1632 | 2 |
| 1642 | 2 |
| 1637 | 2 |
| 1633 | 2 |
| 1643 | 2 |
| 1641 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18842728 | PCNA INHIBITORS AND USES THEREOF | WARD, PAUL V | — | §112 | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18816718 | T CELLS FOR EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS AND OTHER RECEPTORS | POPA, ILEANA | — | §103 | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18754973 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | BURKHART, MICHAEL D | — | §102 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18711338 | METHODS OF PREVENTING, TREATING, OR REDUCING THE SEVERITY OF CORONAVIRUS DISEASE 2019 (COVID-19) | KINSEY WHITE, NICOLE ERIN | — | §102§103§112DP | Non-Final OA | — | Pending | May 17, 2024 |
| 18711088 | METHODS OF PREVENTING, TREATING, OR REDUCING THE SEVERITY OF COVID-19 IN IMMUNOCOMPROMISED BLOOD CANCER PATIENTS | WANG, RUIXUE | — | §103§112 | Non-Final OA | — | Pending | May 16, 2024 |
| 18711073 | SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES | CHESTNUT, BARRY A | — | §102§103§112DP | Non-Final OA | — | Pending | May 16, 2024 |
| 18653869 | COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY | GIBBS, TERRA C | 1635 | §102§103 | Non-Final OA | 29d | Pending | May 02, 2024 |
| 18702614 | CLOSTRIDIUM BUTYRICUM COMPOSITIONS AND METHODS OF USING THE SAME | GANGLE, BRIAN J | 1645 | §102§112Other | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18682713 | CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING gD AND ONCOLYTIC VIRUSES FOR CANCER THERAPY AND TREATMENT OF HSV | LANDSMAN, ROBERT S | — | §103 | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18567094 | COMPOSITIONS AND METHODS FOR ISLET CELL TRANSPLANTS | GRABER, JAMES J | 1631 | §102§103 | Final Rejection | — | Pending | Dec 05, 2023 |
| 18288692 | PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT | WELLS, LAUREN QUINLAN | 1626 | §103DP | Final Rejection | — | Pending | Oct 27, 2023 |
| 18488859 | TREATMENT OF CANAVAN DISEASE | BERTOGLIO, VALARIE E | 1632 | §102Other | Final Rejection | 21d | Pending | Oct 17, 2023 |
| 18554286 | CANCER TREATMENT BY TARGETING PROTEINS OR INTERACTIONS OF EPHRINB-RGS3-KIF20A-SEPT7 AXIS | MEYERING, SHABANA SHABBEER | 1635 | §102§103§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18284413 | CAR T CELL THERAPY AND IFN GAMMA | LEE, YIE CHIA | 1642 | §103§112 | Final Rejection | 9d | Pending | Sep 27, 2023 |
| 18548677 | T-CELLS FOR ANTI-HIV CAR-T THERAPY AND METHODS OF USE | CHASE, CAROL ANN | 1646 | §103§112 | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18277367 | TRUNCATED DOMAIN IV EGFR AND USES THEREOF | BELYAVSKYI, MICHAIL A | 1644 | §103 | Non-Final OA | 28d overdue | Pending | Aug 15, 2023 |
| 18361492 | METHODS OF TREATING A CORONAVIRUS INFECTION | KLINKEL, KORTNEY L | 1627 | §102§103§112 | Non-Final OA | 28d | Pending | Jul 28, 2023 |
| 18220070 | PREVENTION OR TREATMENT OF WASTING SYNDROME | GROOMS, TIFFANY NICOLE | 1637 | §112 | Non-Final OA | 2d overdue | Pending | Jul 10, 2023 |
| 18271026 | NATURAL KILLER CELLS ENGINEERED TO REDUCE OR ELIMINATE CBL-B AND USES THEREOF | SUNSHINE, HANNAH LOUISE | 1647 | §101§102§103§112 | Non-Final OA | 48d | Pending | Jul 05, 2023 |
| 18266443 | COMPOSITIONS AND USES OF CD19 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED IMMUNE CELLS | BENAVIDES, JENNIFER ANN | 1675 | §103 | Final Rejection | 70d | Pending | Jun 09, 2023 |
| 18265544 | COMPOUNDS AND METHODS TO TREAT CYSTIC FIBROSIS | PRONZATI, GINA | 1633 | §102§103 | Non-Final OA | 12d | Pending | Jun 06, 2023 |
| 18255503 | PREVENTION AND TREATMENT OF GRAFT-VERSUS-HOST DISEASE (GVHD) | CESARE, JOSEPH DAVID | 1675 | §102§103§112 | Final Rejection | 8d overdue | Pending | Jun 01, 2023 |
| 18038423 | COMPOSITIONS AND USES OF PSCA TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS | FAUST, AMBER KATHLEEN | 1643 | §103DP | Final Rejection | 42d overdue | Pending | May 23, 2023 |
| 18033777 | ENGINEERED NK CELLS | HAM, JIEUN | 1643 | §102§103Other | Non-Final OA | 56d | Pending | Apr 25, 2023 |
| 18032201 | HYDROPHOBIC DRUGS IN ORGANIC CORE HIGH DENSITY LIPOPROTEIN (HDL) NANOPARTICLES | AL-AWADI, DANAH J | 1615 | §103§112DP | Final Rejection | 66d overdue | Pending | Apr 17, 2023 |
| 18296224 | TREATMENT OF CANAVAN DISEASE | TAKENAKA, RISA | 1632 | §112 | Non-Final OA | — | Pending | Apr 05, 2023 |
| 18026335 | EX VIVO EXPANSION OF REGULATORY T CELLS FOR SUPPRESSION OF GRAFT VERSUS HOST DISEASE | JUEDES, AMY E | 1644 | §103§112 | Final Rejection | 15d | Pending | Mar 14, 2023 |
| 18023536 | NOVEL CELL LINES, METHODS OF PRODUCING NATURAL KILLER CELLS AND USES THEREOF | LUNDE, GRACE HENRY | 1641 | §103§112Other | Non-Final OA | 34d | Pending | Feb 27, 2023 |
| 18022708 | COMPOSITIONS AND METHODS FOR G-PROTEIN-COUPLED RECEPTOR 44 DETECTION | CRAIG, KAILA ANGELIQUE | 1618 | §103§112 | Non-Final OA | — | Pending | Feb 22, 2023 |
| 18042434 | LAMP DETECTION OF SARS-COV-2 IN SALIVA FOR THE RAPID DIAGNOSIS OF COVID-19 | SWITZER, JULIET CAROLINE | 1682 | §103 | Final Rejection | 23d overdue | Pending | Feb 21, 2023 |
| 18020858 | COMPOSITIONS AND USES OF SARS-COV-2 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED NK CELLS | BELYAVSKYI, MICHAIL A | 1644 | §103§112 | Non-Final OA | — | Pending | Feb 10, 2023 |
| 18017982 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | MARTINEZ, TARA L | 1654 | §103Other | Final Rejection | 29d | Pending | Jan 25, 2023 |
| 18017841 | PEPTIDE DESIGN AND GALECTIN-3 INHIBITORS | MACFARLANE, STACEY NEE | 1675 | §103 | Final Rejection | 36d overdue | Pending | Jan 24, 2023 |
| 18066132 | MULTIVALENT MEDITOPES, MEDITOPE-BINDING ANTIBODIES AND USES THEREOF | DIBRINO, MARIANNE | 1641 | §112 | Final Rejection | 50d overdue | Pending | Dec 14, 2022 |
| 18073397 | 3 FLAP OKAZAKI FRAGMENTS AND USES THEREOF | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103§112 | Final Rejection | — | Pending | Dec 01, 2022 |
| 17998011 | METHODS FOR ORGANOIDS PRODUCTION | MARCHESCHI, MICHAEL A | 1796 | §102§103§112 | Non-Final OA | — | Pending | Nov 04, 2022 |
| 17997351 | TAGGED GENE EDITING TECHNOLOGY FOR CLINICAL CELL SORTING AND ENRICHMENT | PYLA, EVELYN Y | 1633 | §103 | Non-Final OA | — | Pending | Oct 27, 2022 |
| 17932239 | SYNTHETIC MODIFIED VACCINIA ANKARA (sMVA) BASED CORONAVIRUS VACCINES | QIAN, CELINE X | 1637 | §103§112DP | Final Rejection | 217d overdue | Pending | Sep 14, 2022 |
| 17910459 | DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS COMPRISING IL-13 AND CHLOROTOXIN FOR CANCER TREATMENT | VIVLEMORE, TRACY ANN | 1638 | §103 | Non-Final OA | 9d overdue | Pending | Sep 09, 2022 |
| 17870024 | CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING CEA AND ANTI-CEA-IL2 IMMUNOCYTOKINES FOR CANCER THERAPY | PATTERSON, SARAH COOPER | 1675 | §103 | Non-Final OA | — | Pending | Jul 21, 2022 |
| 17843073 | ACCESS NEEDLE SYSTEMS AND METHODS | LI, JOHN DENNY | 3798 | §103 | Non-Final OA | 29d | Pending | Jun 17, 2022 |
| 17767398 | CANCER COMBINATION TREATMENTS USING ANTI-STAT3 NUCLEIC ACID CONJUGATES | STONEBRAKER, ALYSSA RAE | 1642 | §103§112DPOther | Non-Final OA | — | Pending | Apr 07, 2022 |
| 17520402 | CHIMERIC ANTIGEN RECEPTORS CONTAINING A CHLOROTOXIN DOMAIN | HINES, JANA A | 1645 | §103 | Final Rejection | 110d overdue | Pending | Nov 05, 2021 |
| 17184987 | Surgical Gauze | ARBLE, JESSICA R | 3781 | §102 | Non-Final OA | 26d | Pending | Feb 25, 2021 |
| 16968504 | PROMOTING AND PROTECTING FUNCTIONAL BETA CELL MASS BY SYNTAXIN 4 ENRICHMENT | CONNORS, ALEXANDRA F | 1634 | §103§112 | Non-Final OA | — | Pending | Aug 07, 2020 |
| 16604151 | P38 GAMMA INHIBITORS AND METHOD OF USE THEREOF | LEE, ANDREW P | 1691 | §112 | Final Rejection | — | Pending | Oct 09, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial